Explore / Peer-reviewed article
Peer-reviewed articleOpen access

Psychedelics as a Treatment for Alzheimer's Disease Dementia.

Vann Jones SA, O'Kelly A

Frontiers in synaptic neuroscienceAug 21, 2020License: open accessUnited Kingdom44 citationsDOI: 10.3389/fnsyn.2020.00034

Abstract

Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic changes and reduce neuroinflammation. This inevitably makes them interesting candidates for therapeutics in dementia. This mini-review will look at the basic science and current clinical evidence for the role of psychedelics in treating dementia, especially early AD, with a particular focus on micro-dosing of the classical psychedelics LSD and psilocybin.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinLSD

Keywords

Alzheimer’s diseaseDementiaMicrodosingPsychedelicPlasticicity

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.